404 related articles for article (PubMed ID: 32914673)
1. Assessment of Drug Proarrhythmic Potential in Electrically Paced Human Induced Pluripotent Stem Cell-Derived Ventricular Cardiomyocytes Using Multielectrode Array.
Bai S; Pei J; Chen K; Zhao Y; Cao H; Tian L; Ma Y; Dong H
SLAS Discov; 2021 Mar; 26(3):364-372. PubMed ID: 32914673
[TBL] [Abstract][Full Text] [Related]
2. Effects of Electrical Stimulation on hiPSC-CM Responses to Classic Ion Channel Blockers.
Wei F; Pourrier M; Strauss DG; Stockbridge N; Pang L
Toxicol Sci; 2020 Apr; 174(2):254-265. PubMed ID: 32040191
[TBL] [Abstract][Full Text] [Related]
3. Electrophysiological characteristics and pharmacological sensitivity of two lines of human induced pluripotent stem cell derived cardiomyocytes coming from two different suppliers.
Goineau S; Castagné V
J Pharmacol Toxicol Methods; 2018; 90():58-66. PubMed ID: 29274391
[TBL] [Abstract][Full Text] [Related]
4. Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays.
Navarrete EG; Liang P; Lan F; Sanchez-Freire V; Simmons C; Gong T; Sharma A; Burridge PW; Patlolla B; Lee AS; Wu H; Beygui RE; Wu SM; Robbins RC; Bers DM; Wu JC
Circulation; 2013 Sep; 128(11 Suppl 1):S3-13. PubMed ID: 24030418
[TBL] [Abstract][Full Text] [Related]
5. Cross - site comparison of excitation-contraction coupling using impedance and field potential recordings in hiPSC cardiomyocytes.
Bot CT; Juhasz K; Haeusermann F; Polonchuk L; Traebert M; Stoelzle-Feix S
J Pharmacol Toxicol Methods; 2018; 93():46-58. PubMed ID: 29940218
[TBL] [Abstract][Full Text] [Related]
6. Human stem cell-derived cardiomyocytes detect drug-mediated changes in action potentials and ion currents.
Gibson JK; Yue Y; Bronson J; Palmer C; Numann R
J Pharmacol Toxicol Methods; 2014; 70(3):255-67. PubMed ID: 25219538
[TBL] [Abstract][Full Text] [Related]
7. The assessment of electrophysiological activity in human-induced pluripotent stem cell-derived cardiomyocytes exposed to dimethyl sulfoxide and ethanol by manual patch clamp and multi-electrode array system.
Hyun SW; Kim BR; Hyun SA; Seo JW
J Pharmacol Toxicol Methods; 2017 Sep; 87():93-98. PubMed ID: 28377112
[TBL] [Abstract][Full Text] [Related]
8. CSAHi study: Detection of drug-induced ion channel/receptor responses, QT prolongation, and arrhythmia using multi-electrode arrays in combination with human induced pluripotent stem cell-derived cardiomyocytes.
Kitaguchi T; Moriyama Y; Taniguchi T; Maeda S; Ando H; Uda T; Otabe K; Oguchi M; Shimizu S; Saito H; Toratani A; Asayama M; Yamamoto W; Matsumoto E; Saji D; Ohnaka H; Miyamoto N
J Pharmacol Toxicol Methods; 2017; 85():73-81. PubMed ID: 28163191
[TBL] [Abstract][Full Text] [Related]
9. Action potential-based MEA platform for in vitro screening of drug-induced cardiotoxicity using human iPSCs and rat neonatal myocytes.
Jans D; Callewaert G; Krylychkina O; Hoffman L; Gullo F; Prodanov D; Braeken D
J Pharmacol Toxicol Methods; 2017 Sep; 87():48-52. PubMed ID: 28549786
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Proarrhythmic Potential of Drugs in Optogenetically Paced Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Patel D; Stohlman J; Dang Q; Strauss DG; Blinova K
Toxicol Sci; 2019 Jul; 170(1):167-179. PubMed ID: 30912807
[TBL] [Abstract][Full Text] [Related]
11. Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity.
Yang X; Papoian T
J Appl Toxicol; 2018 Sep; 38(9):1166-1176. PubMed ID: 29484688
[TBL] [Abstract][Full Text] [Related]
12. Multi-parametric assessment of cardiomyocyte excitation-contraction coupling using impedance and field potential recording: A tool for cardiac safety assessment.
Zhang X; Guo L; Zeng H; White SL; Furniss M; Balasubramanian B; Lis E; Lagrutta A; Sannajust F; Zhao LL; Xi B; Wang X; Davis M; Abassi YA
J Pharmacol Toxicol Methods; 2016; 81():201-16. PubMed ID: 27282640
[TBL] [Abstract][Full Text] [Related]
13. hiPSC-CM electrophysiology: impact of temporal changes and study parameters on experimental reproducibility.
Guerrelli D; Pressman J; Salameh S; Posnack N
Am J Physiol Heart Circ Physiol; 2024 Jul; 327(1):H12-H27. PubMed ID: 38727253
[TBL] [Abstract][Full Text] [Related]
14. International Multisite Study of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Proarrhythmic Potential Assessment.
Blinova K; Dang Q; Millard D; Smith G; Pierson J; Guo L; Brock M; Lu HR; Kraushaar U; Zeng H; Shi H; Zhang X; Sawada K; Osada T; Kanda Y; Sekino Y; Pang L; Feaster TK; Kettenhofen R; Stockbridge N; Strauss DG; Gintant G
Cell Rep; 2018 Sep; 24(13):3582-3592. PubMed ID: 30257217
[TBL] [Abstract][Full Text] [Related]
15. Cardiotoxicity Assessment of Drugs Using Human iPS Cell-Derived Cardiomyocytes: Toward Proarrhythmic Risk and Cardio-Oncology.
Satsuka A; Kanda Y
Curr Pharm Biotechnol; 2020; 21(9):765-772. PubMed ID: 31264543
[TBL] [Abstract][Full Text] [Related]
16. Recording of multiple ion current components and action potentials in human induced pluripotent stem cell-derived cardiomyocytes via automated patch-clamp.
Mann SA; Heide J; Knott T; Airini R; Epureanu FB; Deftu AF; Deftu AT; Radu BM; Amuzescu B
J Pharmacol Toxicol Methods; 2019; 100():106599. PubMed ID: 31228558
[TBL] [Abstract][Full Text] [Related]
17. Development of torsadogenic risk assessment using human induced pluripotent stem cell-derived cardiomyocytes: Japan iPS Cardiac Safety Assessment (JiCSA) update.
Kanda Y; Yamazaki D; Osada T; Yoshinaga T; Sawada K
J Pharmacol Sci; 2018 Dec; 138(4):233-239. PubMed ID: 30415824
[TBL] [Abstract][Full Text] [Related]
18. The electrophysiological effects of cardiac glycosides in human iPSC-derived cardiomyocytes and in guinea pig isolated hearts.
Guo L; Qian JY; Abrams R; Tang HM; Weiser T; Sanders MJ; Kolaja KL
Cell Physiol Biochem; 2011; 27(5):453-62. PubMed ID: 21691062
[TBL] [Abstract][Full Text] [Related]
19. Engineered heart tissue models from hiPSC-derived cardiomyocytes and cardiac ECM for disease modeling and drug testing applications.
Goldfracht I; Efraim Y; Shinnawi R; Kovalev E; Huber I; Gepstein A; Arbel G; Shaheen N; Tiburcy M; Zimmermann WH; Machluf M; Gepstein L
Acta Biomater; 2019 Jul; 92():145-159. PubMed ID: 31075518
[TBL] [Abstract][Full Text] [Related]
20. Cross-Site Reliability of Human Induced Pluripotent stem cell-derived Cardiomyocyte Based Safety Assays Using Microelectrode Arrays: Results from a Blinded CiPA Pilot Study.
Millard D; Dang Q; Shi H; Zhang X; Strock C; Kraushaar U; Zeng H; Levesque P; Lu HR; Guillon JM; Wu JC; Li Y; Luerman G; Anson B; Guo L; Clements M; Abassi YA; Ross J; Pierson J; Gintant G
Toxicol Sci; 2018 Aug; 164(2):550-562. PubMed ID: 29718449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
